Isomer-specific contractile effects of a series of synthetic F 2-isoprostanes on retinal and cerebral microvasculature

Free Radical Biology and Medicine

Volumn 36, Issue 2, 2004, Pages 163-172

  Hou, Xin ^a   Roberts II, L Jackson ^b   Gobeil Jr , Fernand ^c   Taber, Douglas F ^d   Kanai, Kazuo ^d   Abran, Daniel ^e   Brault, Sonia ^a,f   Checchin, Daniella ^a,f   Sennlaub, Florian ^a   Lachapelle, Pierre ^f   Varma, Daya R ^f   Chemtob, Sylvain ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d UNIVERSITY OF DELAWARE   (United States)

^e Theratechnologies   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Calcium; Free radicals; Ischemia; Isoprostane; Thromboxane; Vascular endothelium

Indexed keywords

3 METHYL 2 (3 PYRIDYL) 1 INDOLEOCTANOIC ACID; 6,8 DIFLUORO 1,2,3,4 TETRAHYDRO 9 (4 METHYLSULFONYLBENZYL)CARBAZOLE 1 ACETIC ACID; CALCIUM CHANNEL BLOCKING AGENT; FURA 2 ACETOXYMETHYL ESTER; ISOPROSTANE DERIVATIVE; RECEPTOR; SK AND F 96365; THROMBOXANE A2; THROMBOXANE B2;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; CALCIUM TRANSPORT; CONTROLLED STUDY; ENDOTHELIUM CELL; ISOMER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA BLOOD VESSEL; SWINE; VASOCONSTRICTION;

SUS SCROFA;

EID: 1642464743     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2003.10.024     Document Type: Article

References (45)

1. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:1990;9383-9387.
2. Roberts L.J. II, Morrow J.D. Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell. Mol. Life Sci. 59:2002;808-820.
3. Taber D.F., Morrow J.D., Roberts L.J. II A nomenclature system for the isoprostanes. Prostaglandins. 53:1997;63-67.
4. Morrow J.D., Minton T.A., Mukundan C.R., Campbell M.D., Zackert W.E., Daniel V.C., Badr K.F., Blair I.A., Roberts L.J. II Free radical induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 269:1994;4317-4326.
5. Morrow J.D., Awad J.A., Wu A., Zackert W.E., Daniel V.C., Roberts L.J. II Free radical-induced generation of thromboxane-like compounds (isothromboxanes) in vivo. J. Biol. Chem. 271:1996;23185-23190.
6. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28:2000;505-513.
7. O'Connor D.E., Mihelich E.D., Coleman M.C. Stereochemical course of the autoxidative cyclization of lipid hydroperoxides to prostaglandin-like bicylo endoperoxides. J. Am. Chem. Soc. 106:1984;3577-3584.
8. 2α-III, induce cardiomyocyte hypertrophy: differential activation of downstream signaling pathways. J. Biol. Chem. 273:1998;22442-22452.
9. 2α. J. Biol. Chem. 272:1997;27147-27154.
10. 2α, is formed in vivo. Biochim. Biophys. Acta. 1210:1994;244-248.
11. 2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264:1993;C1619-C1624.
12. 2-induced derangements of pulmonary artery endothelial cell barrier function. Prostaglandins Leukotrienes Essent. Fatty Acids. 58:1998;9-16.
13. Cracowski J.L., Devillier P., Durand T., Stanke-Labesque F., Bessard G. Vascular biology of the isoprostanes. J. Vasc. Res. 38:2001;93-103.
14. Hoffman S.W., Moore S., Ellis E.F. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke. 28:1997;844-849.
15. 2α) in immature pig periventricular brain microvessels. Stroke. 31:2000;516-524.
16. 2α. Br. J. Phamacol. 119:1996;1276-1280.
17. 2α on retinal vessels. Am. J. Physiol. 274:1998;R1406-R1416.
18. 2 receptors. J. Clin. Invest. 90:1992;136-141.
19. 2α in rat aortic rings. Prostaglandins. 54:1997;581-599.
20. 2α) by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 269:1999;326-331.
21. Hou X., Roberts L.J. II, Taber D.F., Morrow J.D., Kanai K., Gobeil F. Jr., Beauchamp M.H., Bernier S.G., Lepage G., Varma D.R., Chemtob S. 2,3-Dinor-5,6-dihydro-15-F(2t)-isoprostane: a bioactive prostanoid metabolite. Am. J. Physiol. 281:2001;R391-R400.
22. Beauchamp M.H., Martinez-Bermudez A.K., Gobeil F. Jr., Marrache A.M., Hou X., Speranza G., Abran D., Quiniou C., Lachapelle P., Roberts J. II, Almazan G., Varma D.R., Chemtob S. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J. Appl. Physiol. 90:2001;2279-2288.
23. Brault S., Martinez-Bermudez A.K., Marrache A.M., Gobeil F. Jr., Hou X., Beauchamp M.H., Quiniou C., Almazan G., Lachance C., Roberts L.J. II, Varma D.R., Chemtob S. Selective neuromicrovascular endothelial cell death by 8-iso-prostaglandin F2alpha: possible role in ischemic brain injury. Stroke. 34:2003;776-782.
24. Chemtob S., Hardy P., Abran D., Li D.Y., Peri K., Cuzzani O., Varma D.R. Peroxide-cyclooxygenase interactions in postasphyxial changes in retinal and choroidal hemodynamics. J. Appl. Physiol. 78:1995;2039-2046.
25. Li W., Stephens N.L. Auxotonic loading and airway smooth muscle shortening. Can. J. Physiol. Pharmacol. 72:1994;1458-1468.
26. Hardy P., Abran D., Hou X., Lahaie I., Peri K., Asselin P., Varma D.R., Chemtob S. A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet. Circ. Res. 83:1998;721-729.
27. Merritt J.E., Armstrong W.P., Benham C.D., Hallam T.J., Jacob R., Jaxa-Chamiec A., Leigh B.K., McCarthy S.A., Moores K.E., Rink T.J. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem. J. 271:1990;515-522.
28. 2. J. Pharmacol. Exp. Ther. 291:1999;627-633.
29. Berthiaume N., Hess F., Chen A., Regoli D., D'Orleans-Juste P. Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur. J. Pharmacol. 333:1997;55-61.
30. + channels in endothelium-dependent vasodilation produced by hypercapnia in rat mesenteric vascular beds. Br. J. Pharmacol. 125:1998;168-174.
31. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
32. 2t-isoprostane. Tetrahedron. 54:1998;11767-11782.
33. 2t-isoprostane, a human hormone? J. Am. Chem. Soc. 121:1999;7773-7777.
34. 2-isoprostanes. J. Am. Chem. Soc. 124:2002;13121-13126.
35. Li H., Lawson J.A., Reilly M., Adiyaman M., Hwang S.W., Rokach J., FitzGerald G.A. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc. Natl. Acad. Sci. USA. 96:1999;13381-13386.
36. Himmel H.M., Whorton A.R., Strauss H.C. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension. 21:1993;112-127.
37. Kinsella B.T., O'Mahony D.J., Fitzgerald G.A. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J. Pharmacol. Exp. Ther. 281:1997;957-964.
38. Yura T., Fukunaga M., Grygorczyk R., Makita N., Takahashi K., Badr K.F. Molecular and functional evidence for the distinct nature of F2-isoprostane receptors from those of thromboxane A2. Adv. Prostaglandin Thromboxane Leukotriene Res. 23:1995;237-239.
39. Pratico D., Smyth E.M., Violi F., FitzGerald G.A. Local amplification of platelet function by 8-epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271:1996;14916-14924.
40. 2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br. J. Pharmacol. 135:2002;1276-1280.
41. Morrow J.D., Roberts L.J., Daniel V.C., Awad J.A., Mirochnitchenko O., Swift L.L., Burk R.F. Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo - effects of oxygen tension and glutathione. Arch. Biochem. Biophys. 353:1998;160-171.
42. Fessel J.P., Porter N.A., Moore K.P., Sheller J.R., Roberts L.J. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc. Natl. Acad. Sci. USA. 99:2002;16713-16718.
43. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1997;1-21.
44. Hall E.D. Lazaroids: efficacy and antioxidant mechanism in experimental cerebral ischemia. Krieglstein J., Oberpichler H. Pharmacology of cerebral ischemia. 1990;343-350 Wissenschaftliche Verlagsgesellschaftm, Stuttgart.
45. Ogletree M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc. 46:1987;133-138.